{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:52:21Z","timestamp":1785405141932,"version":"3.56.0"},"reference-count":22,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Primary central nervous system lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL), which affect multiple regions of the neuroaxis, including the brain parenchyma, the orbits, cranial nerves and leptomeninges, without systemic disease. The aim of this study was to review the clinical characteristics as well as the outcome of patients referred to a tertiary academic hospital in Johannesburg (South Africa) with a presumed PCNSL diagnosis based on histology, cerebrospinal fluid (CSF) analysis and neuroimaging.\n\nMethods: This retrospective record review at a tertiary academic hospital in Soweto (Johannesburg), included patients aged \u2265 17 years referred with a presumed diagnosis of PCNSL, based on biopsy-confirmed PCNSL, CSF analysis or neuroimaging, between January 2010 and December 2022. Patient characteristics (laboratory, clinical, treatment(s), outcome) were analysed in three groups based on diagnostic certainty for PCNSL (diagnostic, suspicious, consistent).\n\nResults: The cohort comprised 14 patients, with most cases occurring in People Living with Human Immunodeficiency Virus (PLWH) (n = 10; 71%), with equal representation of male and female patients. The median age of diagnosis was 43 years (17\u201364), with PLWH diagnosed at an earlier mean age of 40 compared to human immunodeficiency virus (HIV)-negative patients (mean age 52). Both surviving patients received between 6 and 8 cycles of high-dose methotrexate (HD-MTX), with one receiving an autologous stem cell transplant. Over half (57%) of the cohort died with a median overall survival of two months (95% CI 1.3\u20132.6).\n\nConclusion: Establishing a PCNSL diagnosis without histology often relies on several ancillary investigations. The high mortality and poor median survival highlight the importance of timely diagnosis and treatment.\n\nContribution: This case series highlights the the complexities of a PCNSL diagnosis in PLWH and will hopefully inspire future work in this area.<\/jats:p>","DOI":"10.4102\/jcmsa.v3i1.135","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:03:48Z","timestamp":1751526228000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary central nervous system lymphomas at a tertiary academic hospital in Johannesburg"],"prefix":"10.4102","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-0438","authenticated-orcid":false,"given":"Garrick E.","family":"Laudin","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5503-9291","authenticated-orcid":false,"given":"Vinitha","family":"Philip","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-0028","authenticated-orcid":false,"given":"Sugeshnee","family":"Pather","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6680-1193","authenticated-orcid":false,"given":"Atul","family":"Lakha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-2685","authenticated-orcid":false,"given":"Romana","family":"Jassat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8132-0484","authenticated-orcid":false,"given":"Faadil","family":"Waja","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7222-8593","authenticated-orcid":false,"given":"Ahshish","family":"Govind","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2070-6170","authenticated-orcid":false,"given":"Lindokuhle","family":"Goqwana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0647-4384","authenticated-orcid":false,"given":"Moosa","family":"Patel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Phillips E, Fox C, Cwynarski K. Primary CNS lymphoma. Curr Hematol Malig Rep. 2014;9(3):243\u2013253. https:\/\/doi.org\/10.1007\/s11899-014-0217-2","DOI":"10.1007\/s11899-014-0217-2"},{"key":"ref1","unstructured":"Kluin P, Deckert M, Ferry J. WHO classification of tumours of haematopoietic and lymphoid tissues. rev. 4th ed. Swerdlow S, Campo E, Harris N, et al., editors. Lyon: International Agency for Research on Cancer, 2017."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rubenstein J, Gupta N, Mannis G, Lamarre A, Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14):2318\u20132330. https:\/\/doi.org\/10.1182\/blood-2013-06-453084","DOI":"10.1182\/blood-2013-06-453084"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Villano J, Koshy M, Shaikh H, Dolecek T, McCarthy B. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414\u20131418. https:\/\/doi.org\/10.1038\/bjc.2011.357","DOI":"10.1038\/bjc.2011.357"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9(1):29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0","DOI":"10.1038\/s41572-023-00439-0"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 2022;36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Patel M, Machailo J, Lakha A, et al. Diffuse large B-cell lymphoma in adults at Chris Hani Baragwanath Academic Hospital. Thromb Haemost Res. 2022;6(3):1082. https:\/\/doi.org\/10.26420\/thrombhaemostres.2022.1082","DOI":"10.26420\/thrombhaemostres.2022.1082"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Scott B, Douglas V, Tihan T, Rubenstein J, Josephson S. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol. 2013;70(3):311. https:\/\/doi.org\/10.1001\/jamaneurol.2013.606","DOI":"10.1001\/jamaneurol.2013.606"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Grant A, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB fast track): An open-label, cluster-randomised trial. Lancet HIV. 2020;7(1):e27\u2013e37. https:\/\/doi.org\/10.1016\/S2352-3018(19)30266-8","DOI":"10.1016\/S2352-3018(19)30266-8"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dian S, Ganiem A, Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: A review. Pathog Glob Health. 2023;117(1):14\u201323. https:\/\/doi.org\/10.1080\/20477724.2022.2083977","DOI":"10.1080\/20477724.2022.2083977"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liu Y, Yao Q, Zhang F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review). Int J Oncol. 2021;58(3):371\u2013387. https:\/\/doi.org\/10.3892\/ijo.2021.5180","DOI":"10.3892\/ijo.2021.5180"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Borges A, Dubrow R, Silverberg M. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014;9(1):34\u201340. https:\/\/doi.org\/10.1097\/COH.0000000000000025","DOI":"10.1097\/COH.0000000000000025"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Newell M, Hoy J, Cooper S, et al. Human immunodeficiency virus-related primary central nervous system lymphoma. Cancer. 2004;100(12):2627\u20132636. https:\/\/doi.org\/10.1002\/cncr.20300","DOI":"10.1002\/cncr.20300"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lee J, Cole S, Achenbach C, et al. Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS One. 2018;13(6):e0197665. https:\/\/doi.org\/10.1371\/journal.pone.0197665","DOI":"10.1371\/journal.pone.0197665"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hyung J, Hong J, Yoon D, et al. Increased serum beta-2 microglobulin during induction chemotherapy associated with poor prognosis in primary central nervous system lymphoma. Blood. 2018;132(suppl 1):2995. https:\/\/doi.org\/10.1182\/blood-2018-99-118221","DOI":"10.1182\/blood-2018-99-118221"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6(4):100213. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213","DOI":"10.1016\/j.esmoop.2021.100213"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: Analysis of the National cancer database. Blood Adv. 2016;1(2):112\u2013121. https:\/\/doi.org\/10.1182\/bloodadvances.2016000927","DOI":"10.1182\/bloodadvances.2016000927"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Schmitt A, Herbrand A, Fox C, et al. Rituximab in primary central nervous system lymphoma \u2013 A systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548\u2013557. https:\/\/doi.org\/10.1002\/hon.2666","DOI":"10.1002\/hon.2666"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Nayak L, Batchelor T. Is it time to revisit R-CHOP for primary CNS lymphoma? Blood. 2019;134(3):221\u2013222. https:\/\/doi.org\/10.1182\/blood.2019001383","DOI":"10.1182\/blood.2019001383"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Seidel S, Kowalski T, Nilius-Eliliwi V, Schroers R, Schlegel U. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: A retrospective analysis. Neurol Res Pract. 2023;5(1):8. https:\/\/doi.org\/10.1186\/s42466-023-00234-y","DOI":"10.1186\/s42466-023-00234-y"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chahin M, Dontu S, Keruakous A, et al. Real-world outcomes for primary CNS lymphoma from a single academic institution: The Augusta experience. Blood. 2023;142(suppl 1):6312. https:\/\/doi.org\/10.1182\/blood-2023-189357","DOI":"10.1182\/blood-2023-189357"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94(10):e1027\u2013e1039. https:\/\/doi.org\/10.1212\/WNL.0000000000008900","DOI":"10.1212\/WNL.0000000000008900"}],"container-title":["Journal of the Colleges of Medicine of South Africa"],"original-title":[],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:03:59Z","timestamp":1751526239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcmsa.org.za\/index.php\/jcmsa\/article\/view\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/jcmsa.v3i1.135","relation":{},"ISSN":["2960-110X"],"issn-type":[{"value":"2960-110X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"a135"}}